1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Alterity Therapeutics Limited

Alterity Therapeutics Limited

ATHE
Alterity Therapeutics LimitedUS flagNASDAQ Capital Market
2.38
USD
-0.05
- -
40.32MMarket Cap

Total Valuation

Alterity Therapeutics Limited carries a market capitalization of 40.32M, placing it among publicly traded companies globally. Its enterprise value stands at 1.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap40.32M
Enterprise Value1.09B

Share Statistics

Alterity Therapeutics Limited currently has 182.55M shares outstanding.

Shares Outstanding182.55M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio26.76
P/TBV Ratio26.76
P/FCF RatioN/A
P/OCF RatioN/A

Financial Position

Alterity Therapeutics Limited maintains a current ratio of 12.98, meaning it holds 13.0x the short-term assets needed to cover near-term liabilities.

Current Ratio12.98
Quick Ratio12.62
Debt / Equity0.37
Debt / EBITDAN/A
Interest CoverageN/A

Stock Price Statistics

Alterity Therapeutics Limited's stock has declined approximately -51.22951% over the past 52 weeks. The 50-day moving average sits at 3.94, while the 200-day moving average is 4.03.

Beta (5Y)N/A
52-Week Price Change-51.22951%
50-Day Moving Average3.94
200-Day Moving Average4.03
Average Volume (20 Days)N/A

Balance Sheet

Alterity Therapeutics Limited holds 40.66M in cash and equivalents against 155,457.00 in total debt, resulting in a net debt position of -33.16M. Total book value stands at 42.40M, with working capital of 42.34M providing operational flexibility.

Cash & Cash Equivalents40.66M
Total Debt155,457.00
Net Debt-33.16M
Equity (Book Value)42.40M
Book Value Per Share0.23
Working Capital42.34M

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-3.50
FCF YieldN/A

Stock Splits

Alterity Therapeutics Limited's most recent stock split took place on January 9, 2023 with a 10:1 split ratio.

Last Split Date1/9/2023
Split Ratio10:1

Scores

Alterity Therapeutics Limited posts an Altman Z-Score of 182.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score182.16